507 related articles for article (PubMed ID: 21106276)
21. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
[TBL] [Abstract][Full Text] [Related]
22. DPP-4 inhibitors in the treatment of type 2 diabetes.
Duez H; Cariou B; Staels B
Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
[TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation.
Kim HJ; Kwak WY; Min JP; Sung SY; Kim HD; Kim MK; Kim HS; Park KJ; Son MH; Kim SH; Lee BJ
Bioorg Med Chem Lett; 2012 Sep; 22(17):5545-9. PubMed ID: 22850208
[TBL] [Abstract][Full Text] [Related]
24. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
26. Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of type 2 diabetes.
Benbow JW; Andrews KA; Aubrecht J; Beebe D; Boyer D; Doran S; Homiski M; Hui Y; McPherson K; Parker JC; Treadway J; Vanvolkenberg M; Zembrowski WJ
Bioorg Med Chem Lett; 2009 Apr; 19(8):2220-3. PubMed ID: 19285862
[TBL] [Abstract][Full Text] [Related]
27. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
Namoto K; Sirockin F; Ostermann N; Gessier F; Flohr S; Sedrani R; Gerhartz B; Trappe J; Hassiepen U; Duttaroy A; Ferreira S; Sutton JM; Clark DE; Fenton G; Beswick M; Baeschlin DK
Bioorg Med Chem Lett; 2014 Feb; 24(3):731-6. PubMed ID: 24439847
[TBL] [Abstract][Full Text] [Related]
28. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
29. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes.
Sutton JM; Clark DE; Dunsdon SJ; Fenton G; Fillmore A; Harris NV; Higgs C; Hurley CA; Krintel SL; MacKenzie RE; Duttaroy A; Gangl E; Maniara W; Sedrani R; Namoto K; Ostermann N; Gerhartz B; Sirockin F; Trappe J; Hassiepen U; Baeschlin DK
Bioorg Med Chem Lett; 2012 Feb; 22(3):1464-8. PubMed ID: 22177783
[TBL] [Abstract][Full Text] [Related]
30. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
[TBL] [Abstract][Full Text] [Related]
31. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
32. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Agrawal R; Bahare RS; Jain P; Dikshit SN; Ganguly S
Mini Rev Med Chem; 2012 Nov; 12(13):1345-58. PubMed ID: 22512582
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
34. Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).
Paliwal S; Seth D; Yadav D; Yadav R; Paliwal S
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):129-40. PubMed ID: 21299434
[TBL] [Abstract][Full Text] [Related]
35. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.
Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS
Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Wu Y; Wu H; Tang L; Wu P; Liu T; Hu Y
Chem Biol Drug Des; 2013 Aug; 82(2):140-6. PubMed ID: 23530834
[TBL] [Abstract][Full Text] [Related]
37. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
Li Q; Meng L; Zhou S; Deng X; Wang N; Ji Y; Peng Y; Xing J; Yao G
Eur J Med Chem; 2019 Oct; 180():509-523. PubMed ID: 31336309
[TBL] [Abstract][Full Text] [Related]
38. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
[TBL] [Abstract][Full Text] [Related]
39. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].
Biftu T; Qian X; Chen P; Feng D; Scapin G; Gao YD; Cox J; Roy RS; Eiermann G; He H; Lyons K; Salituro G; Patel S; Petrov A; Xu F; Xu SS; Zhang B; Caldwell C; Wu JK; Lyons K; Weber AE
Bioorg Med Chem Lett; 2013 Oct; 23(19):5361-6. PubMed ID: 23972441
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
